Glycoengineered insect cells for commercial biologics manufacturing

用于商业生物制品制造的糖基工程昆虫细胞

• 批准号: 9140154
• 负责人: Christoph Geisler
• 金额: $ 44.62万
• 依托单位: GLYCOBAC, LLC
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-30 至 2018-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9140154
• 关键词: Achievement; Address; Antibodies; Applied Research; Area; Baculoviruses; Basic Science; Biological; Biological Process; Biological Sciences; Biomedical Research; Bioreactors; Cell Line; Cells; Cyclic GMP; Data; Disadvantaged; Engineering; Glycoproteins; Hormones; Human; Insecta; Licensing; Mammalian Cell; Manufacturer Name; Marketing; Medicine; Methods; Outcome; Pattern; Performance; Pharmaceutical Preparations; Phase; Polysaccharides; Positioning Attribute; Production; Property; Proteins; Recombinant Proteins; Research; Research Contracts; Rhabdoviridae; Small Business Innovation Research Grant; Source; Structure; System; Testing; Time; Vaccines; Validation; Virus; base; cell bank; clinical efficacy; clinically relevant; commercialization; design; immunogenic; improved; influenza virus vaccine; interest; public health relevance; scale up; sugar; therapeutic protein; tool; user-friendly

 DESCRIPTION (provided by applicant): Therapeutic proteins, or 'biologics', represent a >$140 billion market that includes a variety of important drugs such as antibodies and hormones. The clinical efficacy of many biologics is determined by their sugar structures, or 'glycans'. Most biologics are manufactured in mammalian cells because they add human-type glycans, which are needed for the drug to function effectively. However, mammalian cells have some serious disadvantages. For example, it takes a long time to establish production cell lines, and mammalian cells can produce immunogenic glycans. The baculovirus / insect cell system (BICS) offers an attractive alternative system for biologics manufacturing, as it lacks these disadvantages. However, the BICS is currently limited by its inability to produce proteins with human-type glycans. GlycoBac has developed tools and methods to 'glycoengineer' insect cells, allowing them to add human-type glycans to recombinant proteins. In Phase I of this SBIR project, GlycoBac established the feasibility of producing several insect cell lines that can efficiently produce proteins with clinically relevant human-type glycan structures. Recently, it was discovered that GlycoBac's insect cells harbor a previously unknown virus. In Phase II, we will remove this adventitious agent using a proprietary method recently developed by GlycoBac. This will improve the biosafety profile of our glycoengineered cell lines and increase their value for biologics production. We will also produce two new cell lines that add two different kinds of 4-branched glycans to proteins. Such glycans are known to improve the efficacy for some vaccines and other biologics. Another Phase II Aim is to demonstrate the robustness and scalability of our new cell lines, as a key requirement for commercial use of the new cell lines will be demonstrated utility under production conditions. Finally, we will generate cell banks for two glycoengineered cell lines. These will be selected based on the performance of the cell lines combined with commercial prospects. In summary, our project is designed to develop glycoengineered BICS into a versatile platform with proven utility for the production of safe and efficacious biologics at production scales. The outcome of this Phase II SBIR project is expected to be a set of insect cell lines that can be used to produce a wide range of biologics with the specific human-type glycans that provide optimal efficacy for a particular application. The proposed products will have high potential impact as new tools for commercial protein manufacturing. GlycoBac also will make glycoengineered BICS available for academic and industrial, basic and applied research. Thus, the tools generated in this project will have a significant and broad impact on human medicine and diverse areas of basic biomedical research.

 描述（由申请人提供）：治疗性蛋白质或“生物制剂”代表了超过1400亿美元的市场，其中包括各种重要药物，如抗体和激素。许多生物制剂的临床疗效取决于其糖结构或“聚糖”。大多数生物制剂是在哺乳动物细胞中生产的，因为它们添加了人类型聚糖，这是药物有效发挥作用所必需的。然而，哺乳动物细胞有一些严重的缺点。例如，建立生产细胞系需要很长时间，而哺乳动物细胞可以产生免疫原性聚糖。 杆状病毒/昆虫细胞系统（BICS）提供了一个有吸引力的替代系统的生物制品生产，因为它没有这些缺点。然而，BICS目前受限于其不能产生具有人型聚糖的蛋白质。GlycoBac已经开发出了“糖工程”昆虫细胞的工具和方法，使它们能够将人类类型的聚糖添加到重组蛋白中。在SBIR项目的第一阶段，GlycoBac确定了生产几种昆虫细胞系的可行性，这些细胞系可以有效地生产具有临床相关人类型聚糖结构的蛋白质。 最近，人们发现GlycoBac的昆虫细胞中含有一种以前未知的病毒。在第二阶段，我们将使用GlycoBac最近开发的专有方法去除这种外源因子。这将改善我们的糖工程细胞系的生物安全性，并增加其在生物制剂生产中的价值。我们还将生产两种新的细胞系，它们将两种不同的4-分支聚糖添加到蛋白质中。已知此类聚糖可改善某些疫苗和其他生物制剂的功效。另一个II期目标是证明我们的新细胞系的稳健性和可扩展性，因为新细胞系商业用途的关键要求将在生产条件下证明实用性。最后，我们将为两种糖工程化细胞系生成细胞库。这些将根据细胞系的性能结合商业前景进行选择。 总之，我们的项目旨在将糖工程化的BICS开发成一个多功能平台，该平台已被证明可用于在生产规模上生产安全有效的生物制剂。该二期SBIR项目的成果预计将是一组昆虫细胞系，可用于生产具有特定人型聚糖的各种生物制剂，为特定应用提供最佳功效。 拟议的产品将作为商业蛋白质制造的新工具具有很高的潜在影响。GlycoBac还将使糖工程BICS可用于学术和工业，基础和应用研究。因此，该项目产生的工具将对人类医学和基础生物医学研究的各个领域产生重大而广泛的影响。